RECRUITING Phase 4 ClinicalTrials.gov

The Impact of Dietary Salt on the Severity of Eczema

Sponsor: University of California, San Francisco • ClinicalTrials.gov ID: NCT07447063

Registry updated: 2026-09-10

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

The goal of this clinical trial is to evaluate the feasibility of low-sodium diet to improve eczema severity. The main questions it aims to answer are: * Does a low-sodium diet improve eczema severity? * How does a low-sodium diet impact skin sodium concentration? * Is skin sodium concentration associated with eczema severity? Researchers will ask all participant to follow a low-sodium diet, then compare sodium tablets to a placebo (a look-alike substance that contains no drug) to specifically examine the impact of altering sodium intake. Participants will: * Follow a low-salt diet for the duration of the 24-week study * Take sodium chloride tablets every day for 5 weeks followed by a placebo every day for 5 weeks after a 2-week washout period, or vice versa * Complete up to 4 virtual check-in visits * Visit the clinic 4 times to answer questionnaires, provide bio samples, complete dietary recalls, and undergo non-contrast sodium MRI

Interventions

Sodium chloride tablets (Drug)
During the 5-week long sodium tablet intervention period, participants will receive five 1 g sodium chloride tablets each morning and four 1 g sodium chloride tablets each evening. Each sodium chloride tablet will contain 0.394 g or 17 mmol of sodium.
Placebo Tablets (Other)
During the 5-week long placebo period, participants will receive five placebo tablets each morning and four placebo tablets each evening

Eligibility criteria

Inclusion Criteria: * Participants ages 18 years * Willing and able to undergo non-contrast MRI. Exclusion Criteria: * Contraindications to MRI (such as cardiac pacemakers, claustrophobia, non-compatible intracranial vascular clips, IUDs, or other implants) * A cardiac event in the past 6 months * Impaired function of the liver or kidney (glomerular filtration rate \<60 mL/min) * Medications that influence sodium excretion (e.g., diuretics or SGLT2 inhibitors) * Antibiotic or immunomodulatory medications within the last month * Contraindications to sodium tablets (Topical medications used exclusively on the head/neck or hands/feet (e.g., antifungal nail treatment, antidandruff shampoo, acne cleansers) are acceptable. Topical and systemic eczema treatments are acceptable if the participant has been on a stable dose for at least 2 months and still meets the severity entry criteria. Patients on dupilumab will not be excluded if they have been on dupilumab for at least two months and still meet the disease severity inclusion criteria.)

Conditions

Eczema Atopic Dermatitis

Locations

San Francisco VA Medical Center — San Francisco, California, United States
UCSF Mt Zion Campus — San Francisco, California, United States

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment